Novo Nordisk Gains on Diabetes Drug Outperformance

about 1 month ago

Alexis Christoffers

"Novo Nordisk ADRs ticker NVO rallying more than 6% today. This coming after a study showed that its diabetes drug outperformed Eli Lilly's. So Ozempic, that's the Novo drug, outperforming Eli Lilly's older drug, Trulicity, in a real world survey of certain U.S. patients. This showed that Medicare patients who took Ozempic were 23% less likely to have a heart attack or stroke."

Novo Nordisk (NVO) rallied over 6% today after a real world study demonstrated that its diabetes drug, Ozempic, delivered better outcomes than Eli Lilly's Trulicity. However, despite the rally, the stock remains down 53% over the past 12 months, highlighting potential for a turnaround amidst inherent long-term challenges.

Related Stocks